Age-Appropriateness of Oral Formulations Authorized for Pediatrics

Authors:

Abstract
Purpose: Pediatric global regulatory initiatives have come into place to address gaps in evidence-based medicine for children. Objective of this study was to assess age-appropriateness of oral pediatric formulations authorized through the U.S. Food and Drug Administration’s Pediatric Rule, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act. Methods: Formulation age-appropriateness was assessed using an adapted version of the World Health Organization pediatric quality product profile assessment tool. Evaluations encompassed four product attributes across pediatric subgroups: dose and dose flexibility, patient acceptability, excipient safety and administration considerations. Each attribute was scored on a three-point scale: 1 indicating high risk, 2 moderate risk, and 3 low risk. Results: 214 oral formulations were evaluated. Age-appropriateness remains a concern; with less than one third of authorized oral formulations for neonates meeting criteria for age-appropriateness, in comparison to 66% for older pediatric populations. Tablets and capsules constitute 58% of formulations indicated for pediatrics, despite tablet sizes often being unsuitable for younger children. Liquid formulations for neonates present a significant oversight, as they frequently contain excipients of potential concern. As children age, swallowability of the dosage form appears to be deprioritized, with only 37% of unswallowable large size tablets for school-aged children, available in alternative dosage forms such as granules, or solids for dispersions. Conclusions: Significant formulation gaps persist in pediatric medicine, with acceptability and excipient safety presenting highest risk. The potential of non-conventional solid dosage forms remains underutilized, underscoring the need for regulatory frameworks to support development of pediatric medicines.

This publication has 32 references indexed in Scilit: